NCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
Clinical Trials
24 trialsNCT04174196 2025-12-02
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02136134 2025-08-29
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01946477 2025-06-06
POM MM 014
Celgene
Phase 2 Completed
NCT02506959 2025-03-18
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05350163 2024-12-10
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
Baptist Health South Florida
Phase 1 Terminated
NCT06429150 2024-06-10
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT06435910 2024-06-10
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Shenzhen Geno-Immune Medical Institute
Phase 1 Recruiting
NCT02184533 2024-05-28
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
Stanford University
Phase 1 Completed
NCT02547662 2023-10-30
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Mayo Clinic
Phase 2 Completed
NCT02544308 2022-12-23
IDRIS
University College, London
Phase 3 Active not recruiting
NCT03312868 2022-04-06
Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma
Instituto do Cancer do Estado de São Paulo
Phase 2 Terminated
NCT00421525 2021-08-16
Phase I/II Study of hLL1 in Multiple Myeloma
Gilead Sciences
Phase 1/2 Completed
NCT04665076 2020-12-11
Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown
NCT00821249 2020-10-19
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Pfizer
Phase 1/2 Completed
NCT01248923 2020-09-30
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Array BioPharma
Phase 1 Completed
NCT04162119 2019-11-18
Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma
Chinese PLA General Hospital
Phase 2 Unknown
NCT04065308 2019-08-22
Dara_DCEP
Seoul National University Hospital
Phase 2 Unknown
NCT00109889 2017-04-24
S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma
SWOG Cancer Research Network
Phase 2 Terminated
NCT00569868 2011-08-12
UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma
University of Arkansas
Phase NA Completed
NCT01199718 2011-06-15
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Cylene Pharmaceuticals
Phase 1 Unknown
NCT00081757 2010-07-02
An Open Protocol for the Compassionate Use of Thalidomide
University of Arkansas
Phase 1/2 Completed
NCT00988312 2009-10-02
Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
University Hospital Carl Gustav Carus
Phase 1 Completed
NCT00781170 2009-05-28
Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Completed